DCVC Bio — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Latus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise.
AI & Machine LearningBiotechDeep TechHealthtechPhiladelphia, US
Co-investorsBioAdvanceHatch BioFund8VCDCVC (Data Collective)GaingelsKorea Development Bank+1 more
Orca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome.
BiotechDigital HealthHealthtechMedical DevicesCalifornia, US
Ivan Dimov(Founder)inNathaniel Fernhoff(Founder)inJeroen Bekaert, PhD(Co-founder and President)Nate Fernhoff, PhD(Co-founder and Chief Executive Officer)inBob Lowsky(Founder)Everett Meyer(Founder)
Co-investors+ND Capital8VCDCVC (Data Collective)Dream Variation VenturesFelicis VenturesLightspeed Venture Partners+4 more
Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.
BiotechHealthtechMedical DevicesSan Diego, US
Eric Murphy(Chief Executive Officer, Co-Founder, & Director)in
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Frazier Life SciencesLongwood FundNovartis Venture FundOrbiMed+2 more
Transcripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution.
AI & Machine LearningBiotechDeep Tech
Co-investorsBlueYard CapitalGaingelsJAZZ Venture PartnersARCH Venture PartnersInsight PartnersMayo Clinic Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.



__Twitter.png)











